HSPA1A and amyotrophic lateral sclerosis: However, Arimoclomol, a drug which stimulates expression of Hsp70, recently came through Phase II human clinical trials for Amyotrophic Lateral Sclerosis (ALS) with encouraging results, and is on schedule to finish Phase III trials by 2021 (Lanka et al., 2009; Elliott et al., 2020; Orphazyme’s arimoclomol receives US Fast Track Designation in Amyotrophic Lateral Sclerosis, 2020).